Last reviewed 2026-05-19 · How we verify

Furanace (NIFURPIRINOL)

Phase 2 active Small molecule ✓ Verified May 2026

Furanace (generic name: NIFURPIRINOL) is a nifurpirinol drug. It is currently in Phase 2 development.

Nifurpirinol works by interfering with the synthesis of DNA and RNA in microorganisms, ultimately leading to their death.

Nifurpirinol, also known as Furacin, is a small molecule antimicrobial agent developed by Pfizer. It is classified as a nifurpirinol, a class of compounds with antimicrobial properties. The exact target of nifurpirinol is unknown, but it is used to treat various infections, including those caused by bacteria and fungi. Nifurpirinol is not FDA-approved for any indications, and its commercial status is unclear. As a result, there is limited information available on its safety profile and pharmacokinetic properties.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NIFURPIRINOL
Drug class	nifurpirinol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a factory that makes new parts. Nifurpirinol is like a machine that breaks down the factory's blueprint, making it impossible for the microorganisms to make new parts and eventually killing them.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Furanace CI brief — competitive landscape report
Furanace updates RSS · CI watch RSS

Frequently asked questions about Furanace

What is Furanace?

Furanace (NIFURPIRINOL) is a nifurpirinol drug.

How does Furanace work?

Nifurpirinol works by interfering with the synthesis of DNA and RNA in microorganisms, ultimately leading to their death.

What is the generic name of Furanace?

NIFURPIRINOL is the generic (nonproprietary) name of Furanace.

What drug class is Furanace in?

Furanace belongs to the nifurpirinol class. See all nifurpirinol drugs at /class/nifurpirinol.

What development phase is Furanace in?

Furanace is in Phase 2.

Drug class: All nifurpirinol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing